

**Management und Beurteilung des Ansprechens von Ipilimumab
bei Patienten mit Melanom**

**Prise en charge et évaluation de la réponse à l'ipilimumab chez les
patients atteints de mélanome**

Literatur / Références

1. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK et al. New challenges in endpoints for drug development in advanced melanoma. *Clin Cancer Res.* 2012;18(2):336–41.
2. Lens M, Testori A, Ferucci PF. Ipilimumab Targeting CD28–Ctla-4 Axis: New Hope in the Treatment of Melanoma. *Curr Top Med Chem.* 2012;12(1):61–6.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med.* 2012;366(26):2443–54.
4. Dummer R, Guggenheim M, Arnold AW, Brauna R, von Moos R. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. *Swiss Med Wkly.* 2011;141:w13320.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med.* 2010;363(8):711–23. Erratum in: *N Engl J Med.* 2010;363(13):1290.
6. Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. *J Dtsch Dermatol Ges.* 2011;9(4):277–86.
7. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. *Cancer Biother Radiopharm.* 2010;25(6):601–13.
8. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. *Cancer Biother Radiopharm.* 2010;25(6):601–13.
9. Kim R, Emi M, Tanabe K, et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. *Cancer Res.* 2006;66:5527.
10. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer.* 2012;12(4):252–64.
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45(2):228–47
12. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res.* 2009;15(23):7412–20.
13. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? *Clin Cancer Res.* 2009;15(23):7116–8.
14. Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. *Semin Oncol.* 2010;37(5):485–98.
15. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. *Semin Oncol.* 2010;37(5):499–507.
16. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. *Proc Natl Acad Sci USA.* 2003;100(8):4712–7.
17. Yervoy® (Ipilimumab): Fachinformation im Arzneimittelkompendium der Schweiz.
18. Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. *Dig Dis Sci.* 2009;54(11):2538–40.
19. Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB. Mechanisms in endocrinology: ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. *Eur J Endocrinol.* 2012;167(1):1–5.
20. Kaehler KC, Egberts F, Lorigan P, Hauschild A. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. *Melanoma Res.* 2009;19(5):333–4.
21. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. *Ann Oncol.* 2011;22(4):991–3.
22. Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. *J Immunother.* 2004;27(6):478–9.
23. Weber JS, Kähler KC, Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. *J Clin Oncol.* 2012 May 21. [Epub ahead of print]